Optimization of human dose prediction by using quantitative and translational pharmacology in drug discovery

被引:25
作者
Bueters, Tjerk [1 ]
Gibson, Christopher [1 ]
Visser, Sandra A. [2 ]
机构
[1] Merck Res Labs, Dept Pharmacokinet Pharmacodynam & Drug Metab, West Point, PA 19486 USA
[2] Merck Res Labs, Dept Pharmacokinet Pharmacodynam & Drug Metab, Upper Gwynedd, PA 19446 USA
关键词
MODEL-BASED METAANALYSIS; CONCENTRATION-TIME PROFILES; TARGET RESIDENCE TIME; SURROGATE END-POINTS; HUMAN PHARMACOKINETICS; ANIMAL-MODELS; IN-VITRO; PHARMACODYNAMIC MODEL; SYSTEMS PHARMACOLOGY; INHIBITOR RG1678;
D O I
10.4155/fmc.15.143
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
In this perspective article, we explain how quantitative and translational pharmacology, when well-implemented, is believed to lead to improved clinical candidates and drug targets that are differentiated from current treatment options. Quantitative and translational pharmacology aims to build and continuously improve the quantitative relationship between drug exposure, target engagement, efficacy, safety and its interspecies relationship at every phase of drug discovery. Drug hunters should consider and apply these concepts to develop compounds with a higher probability of interrogating the clinical biological hypothesis. We offer different approaches to set an initial effective concentration or pharmacokinetic-pharmacodynamic target in man and to predict human pharmacokinetics that determine together the predicted human dose and dose schedule. All concepts are illustrated with ample literature examples.
引用
收藏
页码:2351 / 2369
页数:19
相关论文
共 93 条
[1]  
Agoram BM, 2012, BIOANALYSIS, V4, P1143, DOI [10.4155/BIO.12.88, 10.4155/bio.12.88]
[2]   Impact of Modeling and Simulation: Myth or Fact? [J].
Allerheiligen, S. R. B. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 96 (04) :413-415
[3]   Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection [J].
Anderson, Peter L. ;
Kiser, Jennifer J. ;
Gardner, Edward M. ;
Rower, Joseph E. ;
Meditz, Amie ;
Grant, Robert M. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2011, 66 (02) :240-250
[4]  
[Anonymous], 2010, CLIN PHARMACOKINETIC
[5]  
[Anonymous], EXPERT OPIN DRUG MET
[6]  
[Anonymous], CPT PHARMACOMETRICS
[7]  
[Anonymous], 7 NOORDW S PHARM PHA
[8]  
[Anonymous], CURR DRUG TARGETS
[9]   Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Encenicline, a Selective α7 Nicotinic Receptor Partial Agonist, in Single Ascending-dose and Bioavailability Studies [J].
Barbier, Ann J. ;
Hilhorst, Martijn ;
Van Vliet, Andre ;
Snyder, Peter ;
Palfreyman, Michael G. ;
Gawryl, Maria ;
Dgetluck, Nancy ;
Massaro, Monica ;
Tiessen, Renger ;
Timmerman, Wia ;
Hilt, Dana C. .
CLINICAL THERAPEUTICS, 2015, 37 (02) :311-324
[10]   Covalent inhibitors in drug discovery: from accidental discoveries to avoided liabilities and designed therapies [J].
Bauer, Renato A. .
DRUG DISCOVERY TODAY, 2015, 20 (09) :1061-1073